bimekizumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	August 23, 2023
Call for patient/clinician input closed	October 17, 2023
Clarification: - Patient input submission received from the ACE, CPN, ASC, CAPA, CAPP, CSA, and CJ
Submission received	October 05, 2023
Submission accepted	October 20, 2023
Review initiated	October 23, 2023
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	January 18, 2024
Deadline for sponsors comments	January 30, 2024
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	March 14, 2024
Expert committee meeting (initial)	March 27, 2024
Draft recommendation issued to sponsor	April 10, 2024
Draft recommendation posted for stakeholder feedback	April 18, 2024
End of feedback period	May 03, 2024
Final recommendation issued to sponsor and drug plans	May 15, 2024
Final recommendation posted	June 03, 2024
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	May 30, 2024
Canada's Drug Agency review report(s) posted	September 19, 2024

Last Updated : September 19, 2024

etranacogene dezaparvovec

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	22-Aug-23
Call for patient/clinician input closed	17-Oct-23
Clarification: - Patient input submission received from the Canadian Hemophilia Society
Submission received	04-Oct-23
Submission accepted	19-Oct-23
Review initiated	20-Oct-23
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	11-Jan-24
Deadline for sponsors comments	22-Jan-24
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	15-Feb-24
Expert committee meeting (initial)	28-Feb-24
Draft recommendation issued to sponsor	11-Mar-24
Draft recommendation posted for stakeholder feedback	21-Mar-24
End of feedback period	08-Apr-24
Final recommendation issued to sponsor and drug plans	19-Apr-24
Final recommendation posted	08-May-24
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	06-May-24
Canada's Drug Agency review report(s) posted	26-Sep-24

Last Updated : September 26, 2024

infliximab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	22-Aug-23
Call for patient/clinician input closed	17-Oct-23
Clarification: - Patient input submission received from the Gastrointestinal Society
Submission received	04-Oct-23
Submission accepted	19-Oct-23
Review initiated	20-Oct-23
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	11-Jan-24
Deadline for sponsors comments	22-Jan-24
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	15-Feb-24
Expert committee meeting (initial)	28-Feb-24
Draft recommendation issued to sponsor	11-Mar-24
Draft recommendation posted for stakeholder feedback	21-Mar-24
End of feedback period	08-Apr-24
Final recommendation issued to sponsor and drug plans	22-Apr-24
Final recommendation posted	09-May-24
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	07-May-24
Canada's Drug Agency review report(s) posted	28-Aug-24

Last Updated : September 3, 2024

cannabidiol

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	18-Aug-23
Call for patient/clinician input closed	17-Oct-23
Clarification: - Patient input submission received from the Canadian Epilepsy Alliance
Submission received	29-Sep-23
Submission accepted	17-Oct-23
Review initiated	18-Oct-23
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	09-Jan-24
Deadline for sponsors comments	18-Jan-24
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	15-Feb-24
Expert committee meeting (initial)	28-Feb-24
Draft recommendation issued to sponsor	12-Mar-24
Draft recommendation posted for stakeholder feedback	21-Mar-24
End of feedback period	08-Apr-24
Final recommendation issued to sponsor and drug plans	18-Apr-24
Final recommendation posted	07-May-24
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	03-May-24
Canada's Drug Agency review report(s) posted	23-Jul-24

Last Updated : July 23, 2024

osilodrostat

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	August 17, 2023
Call for patient/clinician input closed	October 10, 2023
Clarification: - Patient input submission received from Canadian Organization for Rare Disorders
Submission received	October 16, 2023
Submission accepted	October 30, 2023
Clarification: - Additional information has been received and the temporary suspension of the review has been lifted
Review initiated	October 31, 2023
Clarification: - Submission temporarily suspended
Draft CADTH review report(s) provided to sponsor for comment	October 10, 2025
Deadline for sponsors comments	October 22, 2025
CDA-AMC review report(s) and responses to comments provided to sponsor	November 14, 2025
Expert committee meeting (initial)	November 26, 2025
Draft recommendation issued to sponsor	December 08, 2025 To December 10, 2025
Draft recommendation posted for stakeholder feedback	December 18, 2025
End of feedback period	January 09, 2026

Last Updated : July 30, 2025

cemiplimab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	August 16, 2023
Call for patient/clinician input closed	October 10, 2023
Clarification: - Patient input submission received from Canadian Cancer Survivor Network, Lung Cancer Canada - Patient Group, and Lung Health Foundation / The Ontario Lung Association
Submission received	September 27, 2023
Submission accepted	October 13, 2023
Review initiated	October 16, 2023
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	January 17, 2024
Deadline for sponsors comments	January 29, 2024
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	March 01, 2024
Expert committee meeting (initial)	March 13, 2024
Draft recommendation issued to sponsor	March 26, 2024
Draft recommendation posted for stakeholder feedback	April 04, 2024
End of feedback period	April 18, 2024
Final recommendation issued to sponsor and drug plans	May 02, 2024
Final recommendation posted	May 21, 2024
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	May 16, 2024
Canada's Drug Agency review report(s) posted	September 18, 2024

Last Updated : September 18, 2024

cannabidiol

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	14-Aug-23
Call for patient/clinician input closed	10-Oct-23
Clarification: - Patient input submission received from the Canadian Epilepsy Alliance
Submission received	25-Sep-23
Submission accepted	11-Oct-23
Review initiated	12-Oct-23
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	03-Jan-24
Deadline for sponsors comments	12-Jan-24
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	15-Feb-24
Expert committee meeting (initial)	28-Feb-24
Draft recommendation issued to sponsor	12-Mar-24
Draft recommendation posted for stakeholder feedback	21-Mar-24
End of feedback period	08-Apr-24
Final recommendation issued to sponsor and drug plans	18-Apr-24
Final recommendation posted	07-May-24
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	03-May-24
Canada's Drug Agency review report(s) posted	27-Jun-24

Last Updated : June 27, 2024

cannabidiol

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	10-Aug-23
Call for patient/clinician input closed	29-Sep-23
Clarification: -Patient input submission received from the Canadian Epilepsy Alliance
Submission received	20-Sep-23
Submission accepted	05-Oct-23
Review initiated	06-Oct-23
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	21-Dec-23
Deadline for sponsors comments	09-Jan-24
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	15-Feb-24
Expert committee meeting (initial)	28-Feb-24
Draft recommendation issued to sponsor	12-Mar-24
Draft recommendation posted for stakeholder feedback	21-Mar-24
End of feedback period	08-Apr-24
Final recommendation issued to sponsor and drug plans	18-Apr-24
Final recommendation posted	07-May-24
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	03-May-24
Canada's Drug Agency review report(s) posted	14-Aug-24

Last Updated : August 15, 2024

nirmatrelvir/ritonavir

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	03-Aug-23
Call for patient/clinician input closed	25-Sep-23
Clarification: - Patient input submission received from the Gastrointestinal Society, Lung Health Foundation, Save Your Skin Foundation and Sickle Cell Awareness Group of Ontario
Submission received	15-Sep-23
Submission accepted	29-Sep-23
Review initiated	03-Oct-23
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	07-Nov-23
Deadline for sponsors comments	14-Nov-23
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	08-Dec-23
Expert committee meeting (initial)	20-Dec-23
Draft recommendation issued to sponsor	09-Jan-24
Draft recommendation posted for stakeholder feedback	18-Jan-24
End of feedback period	02-Feb-24
Clarification: - Reconsideration: major revisions requested by sponsor
Expert committee meeting	27-Mar-24
Final recommendation issued to sponsor and drug plans	11-Apr-24
Final recommendation posted	30-Apr-24
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	25-Apr-24
Canada's Drug Agency review report(s) posted	09-Jul-24

Last Updated : July 9, 2024

fidanacogene elaparvovec

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	June 20, 2023
Call for patient/clinician input closed	August 14, 2023
Clarification: - Patient input submission received from Canadian Hemophilia Society (CHS)
Submission received	August 01, 2023
Submission accepted	August 16, 2023
Review initiated	August 17, 2023
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	November 02, 2023
Deadline for sponsors comments	November 14, 2023
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	December 08, 2023
Expert committee meeting (initial)	December 20, 2023
Draft recommendation issued to sponsor	January 11, 2024
Draft recommendation posted for stakeholder feedback	January 18, 2024
End of feedback period	February 02, 2024
Final recommendation posted	March 06, 2024
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	March 04, 2024
Canada's Drug Agency review report(s) posted	June 05, 2024

Last Updated : June 5, 2024